NCT05732064View on ClinicalTrials.gov

Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep Quality

PHASE4CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

May 22, 2023

Primary Completion Date

April 20, 2025

Study Completion Date

July 26, 2025

Conditions
Breast CancerPerioperative PeriodDexmedetomidineEsketamineSleep Quality
Interventions
DRUG

Dexmedetomidine

Dexmedetomidine 0.5 microgram/kg (300 microgram/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.

DRUG

Esketamine

Esketamine 0.2 mg/kg (25 mg/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.

DRUG

Normal saline

Normal saline of same volume is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.

Trial Locations (1)

100034

Peking University First Hospital, Beijin

All Listed Sponsors
lead

Peking University First Hospital

OTHER

NCT05732064 - Dexmedetomidine-esketamine Combined Nasal Administration and Perioperative Sleep Quality | Biotech Hunter | Biotech Hunter